

Day 1: Monday, 12.10.2026

13.30 – 13.45	Opening remarks
Session 1: Methodological and Regulatory Aspects of Diagnostic Technologies	
13.45 – 14.05	Decentralized sampling considerations in the context of pandemic preparedness and interventions <i>Andreas Wieser (Fh ITMP-IIP/KUM)</i>
14.05 – 14.25	Development of a Novel IVD Test requirements/challenges on the way to CE under IVDR <i>Krutarth Patel (Fh ITMP-IIP)</i>
14.25 – 14.45	Phage based technologies <i>Peter Braun (Fh ITMP-IIP)</i>
14.45 – 15.30	Break & Networking
15.30 – 17.00	Safety instructions and Experiments in small groups A & B
Session 2: AI-Based Diagnostic Tools and Future Infection Preparedness	
17.15 – 17.35	AI-designed de novo proteins as next-generation antibody alternatives for infectious disease diagnostics <i>Moritz Ertelt (Fh ITMP-IIP)</i>
17.35 – 18.00	Predicting and preparing for future Infections <i>Andreas Hauser (Fh ITMP-IIP)</i>
18.00 – 18.05	Closing remarks Day 1
19.30	Social event (Optional; participation at own expense)

Day 2: Tuesday, 13.10.2026

8.30 – 8.45	Opening remarks
Session 3: Immunodiagnostics in Infectious and Immune-Associated Diseases	
8.45 – 9.05	Yellow Fever Virus as a Model for Flavivirus Monoclonal Antibody Discovery <i>Satyajit Nanda (Fh ITMP-IIP/KUM)</i>
9.05 – 9.25	From Development to Clinical Performance: The Elecsys® Dengue Ag Immunoassay <i>Simon Jochum (Roche, Penzberg)</i>
9.25 – 9.45	Liquid Footprints for sepsis diagnostics and other immune-associated 'complex diseases' <i>Mirko Sonntag (Fh IGB, Stuttgart)</i>
9.45 – 10.30	Break & Networking
10.30 – 12.00	Experiments in small groups - Switch A & B
12.00 – 13.30	Lunch
Session 4: Translational Approaches in Diagnostics, Treatment, and Biomanufacturing	
13.30 – 13.50	Developing New Vaccines & Immunomonitoring: Two Sides of the Same Coin <i>Ralf Wagner (Fh ITMP-IIP/Uni Regensburg)</i>
13.50 – 14.10	Aerosol-based Diagnostics and Treatment: Challenges and Possibilities <i>Christoph Haisch (Fh ITMP-IIP)</i>
14.10 – 14.30	Closing the Gap: Translating Biotech Innovation into GMP Manufacturing <i>Hagen Richter (Wacker)</i>
14.30 – 14.45	Closing remarks Day 2